07.11.13
An abstract of Dr. Jay Udani’s study on UC-II was published in the June 2013 issue of Journal of Alternative and Complementary Medicine. UC-II’s ability to improve joint function in healthy, exercising subjects was investigated in a randomized, double-blind, placebo-controlled study. Healthy subjects who had no prior history of arthritic disease or joint pain at rest but experienced joint discomfort with physical activity were included in the study. Research showed benefits for knee extension, exercise duration and recovery.
“By including healthy subjects in this study, and using non-disease endpoints as a measure of efficacy, it is believed that structure/function claims such as ‘may help alleviate exercise-induced joint pain’ can be substantiated when manufacturers include 40 mg of UC-II to their finished product,” stated Jay Martin, vice president of sales and marketing, for InterHealth.
UC-II significantly improved knee joint function as demonstrated by increased knee extension, the study primary endpoint, compared to placebo in healthy, exercising subjects. Knee extension is necessary for daily function and sport activities.
According to the lead study researcher, Dr. Jay Udani, “Loss of knee extension has been shown to negatively impact the function of the lower extremity. For example, loss of knee extension can cause altered gait patterns affecting ankles and the hip which could result in difficulty with running and jumping.”
Subjects were placed on a standardized stepmill procedure until they complained of knee discomfort of at least 5 on a zero to 10 point Likert scale. While on the stepmill, the “time to onset of discomfort” was measured. When subjects got off the stepmill the “time to offset of discomfort” was measured as well. These were secondary study endpoints. Subjects exercised longer before experiencing joint discomfort and recovered faster from joint discomfort after exercising compared to baseline.
For further information: www.interhealthusa.com
“By including healthy subjects in this study, and using non-disease endpoints as a measure of efficacy, it is believed that structure/function claims such as ‘may help alleviate exercise-induced joint pain’ can be substantiated when manufacturers include 40 mg of UC-II to their finished product,” stated Jay Martin, vice president of sales and marketing, for InterHealth.
UC-II significantly improved knee joint function as demonstrated by increased knee extension, the study primary endpoint, compared to placebo in healthy, exercising subjects. Knee extension is necessary for daily function and sport activities.
According to the lead study researcher, Dr. Jay Udani, “Loss of knee extension has been shown to negatively impact the function of the lower extremity. For example, loss of knee extension can cause altered gait patterns affecting ankles and the hip which could result in difficulty with running and jumping.”
Subjects were placed on a standardized stepmill procedure until they complained of knee discomfort of at least 5 on a zero to 10 point Likert scale. While on the stepmill, the “time to onset of discomfort” was measured. When subjects got off the stepmill the “time to offset of discomfort” was measured as well. These were secondary study endpoints. Subjects exercised longer before experiencing joint discomfort and recovered faster from joint discomfort after exercising compared to baseline.
For further information: www.interhealthusa.com